UMedic Group Bhd

UMedic Group Bhd maintains a strong liquidity position, with a current ratio of 9.48, indicating that the company has significantly more current assets than current liabilities. The company's liquidity_fpt metric suggests that it is well-positioned to meet short-term obligations without relying on external financing. However, the risk assessment notes that net cash is negative after subtracting total debt, which could signal potential liquidity constraints if cash flow from operations were to decline.

In terms of profitability, UMedic Group Bhd reported a net income of MYR 15.83 million in the latest period, translating to a return on equity (ROE) of 2.3% and a return on assets (ROA) of 1.99%. These figures are below the industry median for ROE and ROA, suggesting that the company is underperforming relative to its peers in terms of capital efficiency and asset utilization. The operating margin of 19.66% (calculated as operating income of MYR 2.30 million divided by revenue of MYR 11.69 million) is in line with the industry average, but the net profit margin of 13.54% is slightly below the median, indicating that the company may be facing higher operating expenses or tax burdens compared to its peers.

The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no material geographic diversification reported. This lack of diversification could expose the company to regional economic or regulatory risks, particularly in the healthcare sector, which is subject to frequent policy changes and reimbursement adjustments.

Looking ahead, UMedic Group Bhd is projected to experience modest revenue growth in the current fiscal year, with a year-over-year increase of approximately 3.5% expected. However, the outlook for the next fiscal year is more uncertain, with analysts forecasting a potential decline in revenue due to increased competition and regulatory pressures. The company's capital expenditure of MYR 1.78 million in the latest period suggests a cautious approach to expansion, with a focus on maintaining operational efficiency rather than aggressive growth.

The risk assessment highlights a medium liquidity risk, primarily due to the company's negative net cash position after accounting for total debt. While the dilution risk is currently low, the absence of strong buy or buy recommendations from analysts suggests that the market may be skeptical about the company's long-term growth prospects. The risk of dilution remains low in the near term, as the company has not issued additional shares recently, and there are no indications of a pending equity offering.

Recent filings and transcripts indicate that UMedic Group Bhd has been focusing on cost optimization and supply chain efficiency to improve its margins. The company has also been exploring new product lines to diversify its revenue streams, although these initiatives are still in the early stages.

UMediC Group Berhad (UMED.KL) currently presents a baseline profile with no material changes or active watcher signals to report. The system indicates this is the first analysis for the ticker, meaning there is no prior basis for computing deltas in performance or sentiment. Consequently, there are no recent shifts in operational metrics, market perception, or strategic developments to highlight. The company’s current structure is characterized by minimal external coverage and institutional engagement. Data shows that UMedic Group Berhad has only one officer on record and zero analysts providing coverage. Furthermore, the firm is not a member of any major indices, and there are no identified top holders, suggesting a lack of significant institutional ownership or broad market tracking at this stage. Market activity surrounding the stock has been virtually non-existent in the recent period. Cross-source signal data from late June through mid-July 2026 reveals zero dispatches per day, with no associated sentiment recorded. This absence of news flow or analyst commentary underscores the low visibility of the stock in current financial media and research channels. Given the lack of material changes, analyst estimates, or financial updates in the available data, the significance of UMedic Group Berhad’s current position is defined by its quiet status. Investors and observers should note that the absence of data points—rather than specific negative events—characterizes the current landscape for UMED.KL, with no new information to alter its baseline profile.

Long-term debt dropped to MYR 48,050 in FY2025, resulting in a negligible debt-to-equity ratio of 0.02.

Cash conversion ratio of 1.01 exceeds the cohort median of 0.84, indicating strong operational cash generation efficiency.

Analysts assign a mean price target of MYR 0.31, implying a modest 3.3% upside from the current market price.

Return on equity of 2.3% outperforms the cohort median of 1.42%, demonstrating superior capital efficiency relative to peers.

Revenue CAGR of -9.4% over four years indicates a persistent long-term downward trajectory in sales growth.

The company faces medium liquidity risk, which could constrain operational flexibility amidst declining cash flows.

Revenue MYR 48.6M, −11,0% YoY; Operating income −14,6% YoY.

• ▍Revenue MYR 48.6M, −11,0% YoY
• ▍Operating income −14,6% YoY
• ▍Net income −9,5% YoY
• ▍Free cash flow −41,9% YoY
• ▍Net margin 16.7%

Revenue MYR 54.6M, +20,1% YoY; Operating income −3,1% YoY.

• ▍Revenue MYR 54.6M, +20,1% YoY
• ▍Operating income −3,1% YoY
• ▍Net income −12,8% YoY
• ▍Free cash flow −24,2% YoY
• ▍Net margin 16.5%

Revenue MYR 45.4M, −10,5% YoY; Operating income +41,9% YoY.

• ▍Revenue MYR 45.4M, −10,5% YoY
• ▍Operating income +41,9% YoY
• ▍Net income +60,5% YoY
• ▍Free cash flow +1,0% YoY
• ▍Net margin 22.7%

Revenue MYR 50.7M, +48,7% YoY; Operating income +27,5% YoY.

• ▍Revenue MYR 50.7M, +48,7% YoY
• ▍Operating income +27,5% YoY
• ▍Net income +26,3% YoY
• ▍Free cash flow +309,6% YoY
• ▍Net margin 12.7%